BriaCell Therapeutics Corp BCTX 深 沪
等待开盘 04-02 09:30:00 美东时间
4.1299
-0.060
-1.43%
华盛通- 最 高4.26
- 今 开4.15
- 成交量 7.95万股
- 最 低 4.08
- 昨 收 4.19
- 总市值 2994.38万
- 52周最高 98.20
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 3.60
- 委 比 33.33%
- 总股本 725.05万
- 历史最高 1860.5799
- 量 比 0.47
- 振 幅 4.30%
- 历史最低 3.60
- 每 手 1
- 风险率 13.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell Therapeutics Reports Rising Losses and Funding Pressure
An announcement from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. On ...
04-01 07:35
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
BriaCell Therapeutics Corp. and its subsidiary BriaPro Therapeutics Corp. have completed an asset purchase transaction under which BriaPro acquired the exclusive license for sCD80, a promising immunotherapy for cancer treatment. BriaPro is now responsible for developing and commercializing sCD80, with BriaCell retaining a significant ownership stake of approximately 78%. As part of the deal, BriaCell provided up to $3 million in funding to suppor...
03-31 20:05
BriaCell Therapeutics To Present Four Posters At 2026 American Association For Cancer Research Annual Meeting
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it
03-18 19:35
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
BriaCell Therapeutics Corp. will present four posters at the 2026 AACR Annual Meeting in San Diego, showcasing positive clinical and preclinical data for its immunotherapies. The posters include results from a pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, analyses of Phase 2 data, and preclinical findings on Bria-OTS+, a next-generation personalized immunotherapy targeting breast, prostate, lung, and melanoma cancers. The...
03-18 11:30
BriaCell Secures Prime Spotlight at Major 2026 Cancer Conference to Reveal 'Next-Gen' Personalized Immunotherapy Progress
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four
03-10 19:36
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
BriaCell Therapeutics Corp. announced that four abstracts related to its immunotherapy platform, including its Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor, have been accepted for poster presentation at the 2026 AACR Annual Meeting in San Diego. The posters will highlight research supporting its next-generation immunotherapy program, Bria-OTS+, and additional details will be available on March 17, 2026.
03-10 11:30
BriaCell Restructures Soluble CD80 Program via BriaPro Deal
The latest announcement is out from BriaCell Therapeutics ( ($TSE:BCT) ). On Fe...
02-21 05:47
BriaCell Phase 3 Breast Cancer Trial Clears Fifth Straight Safety Review, Study Continues
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company"), clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the
02-17 20:38
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. announced that the independent Data Safety Monitoring Board (DSMB) has recommended the continuation of their pivotal Phase 3 study of Bria-IMT™ plus immune checkpoint inhibitor in patients with metastatic breast cancer, citing no safety concerns. This marks the fifth consecutive positive recommendation from the DSMB, supporting the favorable safety profile observed. The Phase 3 study is conducted under FDA Fast Track D...
02-17 12:30
